Immunocore Holdings (IMCR) | Financial Analysis & Statements
Immunocore Holdings plc – ADR Small-cap Healthcare
TL;DR: Financial Overview - Revenue, Profits & Key Metrics
Latest Quarterly: Dec 2025Income Metrics
Revenue
104.5M
Gross Profit
101.8M
97.41%
Operating Income
-19.7M
-18.85%
Net Income
-30.1M
-28.77%
EPS (Diluted)
$-0.60
Balance Sheet Metrics
Total Assets
1.1B
Total Liabilities
686.2M
Shareholders Equity
381.0M
Debt to Equity
1.80
Cash Flow Metrics
Operating Cash Flow
-23.7M
Free Cash Flow
-35.5M
Revenue & Profitability Trend
Quarter Income Flow
Dec 31, 2025
Annual Income Flow
2025
Immunocore Holdings Income Statement From 2021 to 2025
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | 400.0M | 310.2M | 249.4M | 174.4M | 36.5M |
| Cost of Goods Sold | 5.1M | 2.7M | 1.0M | 1.1M | 0 |
| Gross Profit | 394.9M | 307.5M | 248.4M | 173.3M | 36.5M |
| Gross Margin % | 98.7% | 99.1% | 99.6% | 99.4% | 100.0% |
| Operating Expenses | |||||
| Research & Development | 274.9M | 222.2M | 163.5M | 101.9M | 100.2M |
| Selling, General & Administrative | 165.4M | 155.8M | 144.5M | 123.1M | 110.8M |
| Other Operating Expenses | - | - | - | - | -20.2K |
| Total Operating Expenses | 440.3M | 377.9M | 308.0M | 225.0M | 211.1M |
| Operating Income | -45.4M | -70.5M | -59.6M | -51.7M | -174.6M |
| Operating Margin % | -11.3% | -22.7% | -23.9% | -29.7% | -478.5% |
| Non-Operating Items | |||||
| Interest Income | 16.5M | 25.6M | 18.0M | 3.8M | 65.0K |
| Interest Expense | 12.2M | 18.8M | 5.2M | 5.4M | 5.6M |
| Other Non-Operating Income | 21.9M | 10.8M | -14.1M | 12.5M | 216.0K |
| Pre-tax Income | -19.1M | -52.9M | -60.9M | -40.9M | -179.9M |
| Income Tax | 16.4M | -1.8M | -5.6M | 11.7M | 150.0K |
| Effective Tax Rate % | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Net Income | -35.5M | -51.1M | -55.3M | -52.5M | -180.0M |
| Net Margin % | -8.9% | -16.5% | -22.2% | -30.1% | -493.4% |
| Key Metrics | |||||
| EBITDA | -5.9M | -26.4M | -38.5M | -44.3M | -167.0M |
| EPS (Basic) | $-0.71 | $-1.02 | $-1.13 | $-1.09 | $-4.05 |
| EPS (Diluted) | $-0.71 | $-1.02 | $-1.13 | $-1.09 | $-4.05 |
| Basic Shares Outstanding | 50345666 | 49991064 | 38573889 | 36897998 | 35333937 |
| Diluted Shares Outstanding | 50345666 | 49991064 | 38573889 | 36897998 | 35333937 |
Income Statement Trend
Join Our United States Telegram Channel
Get Instant Market Updates: 52-Week High/Low Alerts, Breakout Notifications & Expert Stock Analysis Delivered To Your Phone. Join Traders Making Informed Decisions Daily!
Immunocore Holdings Balance Sheet From 2021 to 2025
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Assets | |||||
| Current Assets | |||||
| Cash & Equivalents | 467.7M | 455.7M | 442.6M | 402.5M | 321.1M |
| Short-term Investments | 396.4M | 364.6M | - | - | - |
| Accounts Receivable | 74.0M | 63.0M | 52.1M | 33.6M | 8.2M |
| Inventory | 6.7M | 5.4M | 4.5M | 692.0K | 0 |
| Other Current Assets | 6.8M | 7.9M | 9.7M | 3.6M | - |
| Total Current Assets | 996.7M | 929.9M | 528.8M | 474.0M | 354.6M |
| Non-Current Assets | |||||
| Property, Plant & Equipment | 83.6M | 78.0M | 73.1M | 63.2M | 30.5M |
| Goodwill | - | - | - | 410.0K | 0 |
| Intangible Assets | - | - | - | - | - |
| Long-term Investments | - | - | - | - | - |
| Other Non-Current Assets | 20.3M | 31.9M | 25.4M | 14.0M | 3.5M |
| Total Non-Current Assets | 70.5M | 79.6M | 68.2M | 52.8M | 52.7M |
| Total Assets | 1.1B | 1.0B | 597.0M | 526.8M | 407.3M |
| Liabilities | |||||
| Current Liabilities | |||||
| Accounts Payable | 24.4M | 25.1M | 17.8M | 14.4M | 10.1M |
| Short-term Debt | 2.0M | 1.5M | 1.4M | 1.9M | 1.7M |
| Current Portion of Long-term Debt | - | - | - | - | - |
| Other Current Liabilities | - | - | - | - | - |
| Total Current Liabilities | 246.7M | 212.2M | 139.0M | 100.8M | 82.6M |
| Non-Current Liabilities | |||||
| Long-term Debt | 434.7M | 431.2M | 82.6M | 79.6M | 84.5M |
| Deferred Tax Liabilities | - | - | - | - | - |
| Other Non-Current Liabilities | - | - | - | - | - |
| Total Non-Current Liabilities | 439.5M | 436.6M | 89.1M | 87.0M | 93.2M |
| Total Liabilities | 686.2M | 648.8M | 228.2M | 187.9M | 175.8M |
| Equity | |||||
| Common Stock | 136.0K | 135.0K | 134.0K | 129.0K | 118.8K |
| Retained Earnings | -831.3M | -795.8M | -744.7M | -689.4M | -649.7M |
| Treasury Stock | - | - | - | - | - |
| Other Equity | - | - | - | - | - |
| Total Shareholders Equity | 381.0M | 360.7M | 368.8M | 338.9M | 231.5M |
| Key Metrics | |||||
| Total Debt | 436.7M | 432.7M | 84.0M | 81.4M | 86.2M |
| Working Capital | 750.0M | 717.7M | 389.8M | 373.1M | 272.0M |
Balance Sheet Composition
Immunocore Holdings Cash Flow Statement From 2021 to 2025
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Operating Activities | |||||
| Net Income | -35.5M | -51.1M | -55.3M | -52.5M | -180.0M |
| Depreciation & Amortization | 3.3M | 4.2M | 4.1M | 5.3M | 7.6M |
| Stock-Based Compensation | 37.7M | 34.2M | 32.5M | 32.9M | 48.9M |
| Working Capital Changes | -18.4M | -14.8M | -41.8M | -51.2M | -34.0M |
| Operating Cash Flow | 6.3M | -23.7M | -58.5M | -67.0M | -167.9M |
| Investing Activities | |||||
| Capital Expenditures | -4.3M | -5.1M | -5.4M | -2.2M | -1.3M |
| Acquisitions | - | - | - | - | - |
| Investment Purchases | -30.0M | -350.0M | - | - | - |
| Investment Sales | 18.0M | - | - | - | - |
| Investing Cash Flow | -16.3M | -355.1M | -5.4M | 689.3K | -1.3M |
| Financing Activities | |||||
| Share Repurchases | - | - | - | - | - |
| Dividends Paid | - | - | - | 0 | 0 |
| Debt Issuance | 0 | 402.5M | 0 | 50.0M | 0 |
| Debt Repayment | 0 | -50.0M | 0 | -50.0M | 0 |
| Financing Cash Flow | 0 | 337.1M | 0 | 135.7M | 265.9M |
| Free Cash Flow | -15.1M | 20.9M | -2.5M | -51.4M | -144.5M |
| Net Change in Cash | -10.1M | -41.8M | -63.9M | 69.4M | 96.7M |
Cash Flow Trend
Immunocore Holdings Key Financial Ratios
Valuation Ratios
P/E Ratio (TTM)
-41.17
Forward P/E
-21.39
Price to Book
3.99
Price to Sales
3.81
PEG Ratio
-1.49
Profitability Ratios
Profit Margin
-8.88%
Operating Margin
0.04%
Return on Equity
-9.58%
Return on Assets
-1.54%
Financial Health
Current Ratio
4.04
Debt to Equity
114.61
Beta
0.83
Per Share Data
EPS (TTM)
$-0.71
Book Value per Share
$7.52
Revenue per Share
$7.95
Peer Financial Comparison
| Company | Market Cap | P/E Ratio | P/B Ratio | ROE | Profit Margin | Debt/Equity |
|---|---|---|---|---|---|---|
| IMCR | 1.5B | -41.17 | 3.99 | -9.58% | -8.88% | 114.61 |
| Vertex | 109.4B | 28.40 | 5.92 | 22.54% | 32.94% | 10.91 |
| Regeneron | 81.0B | 18.00 | 2.45 | 14.86% | 31.41% | 9.51 |
| Recursion | 1.9B | -2.44 | 1.64 | -59.54% | 4.45% | 6.89 |
| Capricor | 2.0B | -15.61 | 6.62 | -46.56% | 0.00% | 4.75 |
| Zymeworks | 2.0B | 3.79 | 7.32 | -26.72% | -76.56% | 6.80 |
Financial data is updated regularly. All figures are in the company's reporting currency.






